Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Roche Says Study Backs Invirase for AIDS




 

Reuters (06/20/97)

Roche, a Switzerland-based pharmaceutical company, reports that a 22-nation study of a triple-drug therapy--including its protease inhibitor Invirase--slowed progression of AIDS by 50 percent, compared to using standard two-drug treatment. The research found that whereas only 76 patients who took the triple-drug combination developed AIDS, 142 of those patients on the two-drug therapy progressed. The pharmaceutical maker noted that the findings would be submitted to regulators to update the labeling of Invirase, which was approved in the United States in late 1995. The researchers in the study followed 3,485 patients between August 1994 and January 1997.



 


Copyright © 1997 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in June 20, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.